The UK has initiated the first human trial of an innovative mRNA-based lung cancer vaccine, BioNTech's BNT116, designed to enhance the body's ability to recognize and attack NSCLC cells. https://lnkd.in/dk5csrqZ
The first human trial of #BNT116, an #mRNA-based #lungcancer #vaccine, has started, and the first patient received the treatment at UCLH. Developed by BioNTech SE, this #cancervaccine targets non-small cell #lung #cancer (#NSCLC) by enhancing the #immune response to cancer cells. Spanning seven countries, the global trial aims to evaluate the safety and efficacy of the vaccine alongside traditional cancer treatments. https://lnkd.in/dRVexJbc